Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

IceCure Medical Ltd. ICCM

Healthcare  —  Medical Devices
1.73 0.00 0.00% as of 25 Sep
Market cap
$6.5M
P/E
0.0×
Revenue Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

IceCure Medical Ltd. (ICCM) Business Profile

Updated before January 2025

Company Overview

IceCure Medical Ltd. (ICCM) is a pioneering medical device company specializing in minimally invasive cryoablation technology for the treatment of tumors. Founded in 2006 and headquartered in Caesarea, Israel, the company has established itself as a leader in the field of cryotherapy. IceCure’s mission is to provide innovative, safe, and effective solutions for the treatment of cancerous and benign tumors, offering patients and healthcare providers alternatives to traditional surgical procedures. The company is led by a team of experienced professionals, including CEO Eyal Shamir, who has been instrumental in driving the company’s growth and global expansion.

Core Business Segments

Cryoablation Technology

IceCure Medical’s flagship product is the ProSense™ system, a state-of-the-art cryoablation device designed to treat tumors by freezing them at sub-zero temperatures. The ProSense™ system is used in various medical fields, including breast cancer, kidney cancer, lung cancer, and bone cancer. The technology is minimally invasive, offering patients a quicker recovery time and fewer complications compared to traditional surgery.

Consumables and Accessories

In addition to the ProSense™ system, IceCure offers a range of consumables and accessories that are essential for the operation of its cryoablation devices. These include cryoprobes, which are used to deliver the freezing energy to the targeted tissue, and other disposable components that ensure the system’s efficiency and safety.

Training and Support Services

IceCure provides comprehensive training and support services to healthcare professionals to ensure the effective use of its cryoablation technology. These services include hands-on training, online resources, and ongoing technical support to help medical teams integrate the ProSense™ system into their practice.

Business Model

IceCure Medical operates on a business-to-business (B2B) model, partnering with hospitals, clinics, and healthcare providers worldwide. The company generates revenue through the sale of its ProSense™ system, as well as recurring revenue from consumables and accessories. IceCure also offers service contracts and training programs, creating additional revenue streams. By focusing on innovation and customer support, the company aims to build long-term relationships with its clients and expand its market presence.

Strategic Direction

IceCure Medical is committed to advancing its cryoablation technology and expanding its applications to new medical fields. The company is actively investing in research and development to improve the ProSense™ system and explore its potential in treating other types of tumors. IceCure also aims to expand its global footprint by entering new markets and forming strategic partnerships with leading healthcare organizations. Sustainability is another key focus, with the company working to minimize the environmental impact of its products and operations.

Competitive Landscape

IceCure Medical operates in a competitive market, facing competition from other companies specializing in minimally invasive tumor treatments. Key competitors include Medtronic, Boston Scientific, and AngioDynamics, which offer alternative technologies such as radiofrequency ablation and microwave ablation. Despite the competition, IceCure differentiates itself through its innovative cryoablation technology, which offers unique advantages in terms of safety, efficacy, and patient comfort.

Risk Factors

Like any medical device company, IceCure Medical faces several risks that could impact its business. These include:

  • Regulatory Risks: The company must comply with stringent regulatory requirements in different countries, which can be time-consuming and costly.
  • Market Dependence: IceCure relies heavily on the success of its ProSense™ system, making it vulnerable to market fluctuations and changes in demand.
  • Supply Chain Disruptions: The company depends on a global supply chain for the production of its devices, which could be affected by geopolitical events, natural disasters, or other disruptions.
  • Competition: The presence of well-established competitors with significant resources poses a challenge to IceCure’s market share.

Recent Developments

IceCure Medical has made significant strides in recent years, including the expansion of its product portfolio and the establishment of new partnerships. In 2023, the company received regulatory approval for the ProSense™ system in several new markets, including China and Brazil, paving the way for increased global adoption. IceCure has also been actively involved in clinical trials to demonstrate the efficacy of its technology in treating various types of tumors, further solidifying its position as a leader in cryoablation.

Investment Considerations

Strengths

  • Innovative Technology: IceCure’s cryoablation technology offers a unique and effective alternative to traditional surgical procedures.
  • Growing Market: The demand for minimally invasive tumor treatments is increasing, providing significant growth opportunities for the company.
  • Global Presence: IceCure has a strong international footprint, with a presence in key markets around the world.

Risks

  • Regulatory Challenges: Navigating the complex regulatory landscape can be a hurdle for the company.
  • Market Competition: The presence of established competitors poses a risk to IceCure’s market share.
  • Dependence on Key Products: The company’s reliance on the ProSense™ system makes it vulnerable to market fluctuations.

Conclusion

IceCure Medical Ltd. is a trailblazer in the field of cryoablation technology, offering innovative solutions for the treatment of tumors. With a strong focus on research and development, a growing global presence, and a commitment to sustainability, the company is well-positioned for future growth. While challenges such as regulatory hurdles and market competition remain, IceCure’s unique technology and strategic direction make it a compelling player in the medical device industry.